| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Talazoparib tosylate (USAN); Talazoparib tosilate (JAN); Talzenna (TN) | ||||||
| Product | TALZENNA (Pfizer Laboratories Div Pfizer), TALZENNA (U.S. Pharmaceuticals) | ||||||
| Formula | C19H14F2N6O. C7H8O3S | ||||||
| Exact mass | 552.1391 | ||||||
| Mol weight | 552.5525 | ||||||
| Structure |  | ||||||
| Class | Antineoplastic DG02942 PARP inhibitor | ||||||
| Remark |
| ||||||
| Efficacy | Antineoplastic, PARP inhibitor | ||||||
| Disease | Breast cancer (BRCA mutated, HER2 negative) [DS:H00031] | ||||||
| Comment | Treatment of solid tumors and hematological malignancies | ||||||
| Target | PARP1 [HSA:142] [KO:K24070] PARP2 [HSA:10038] [KO:K10798] | ||||||
| Pathway |
| ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01X OTHER ANTINEOPLASTIC AGENTS L01XK Poly (ADP-ribose) polymerase (PARP) inhibitors L01XK04 Talazoparib D10733 Talazoparib tosylate (USAN) <US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Talazoparib D10733 Talazoparib tosylate (USAN) Drug groups [BR:br08330] Antineoplastic DG02942 PARP inhibitor DG01865 Talazoparib D10733 Talazoparib tosylate Drug classes [BR:br08332] Antineoplastic DG02942 PARP inhibitor D10733 Talazoparib tosylate Target-based classification of drugs [BR:br08310] Enzymes Transferases (EC2) Pentosyltransferases PARP1 D10733 Talazoparib tosylate (USAN) <US> PARP2 D10733 Talazoparib tosylate (USAN) <US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10733 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10733 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10733 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D10733 Drug groups [BR:br08330] Antineoplastic DG02942 PARP inhibitor DG01865 Talazoparib | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 39 1 C8y C 17.5000 -14.9800 2 C8x C 18.2000 -16.1000 3 C8y C 19.6000 -16.1700 4 C8y C 20.3000 -14.9800 5 C8y C 19.6000 -13.7200 6 C8x C 18.2000 -13.7200 7 C8y C 21.7000 -14.9100 8 N5x N 22.4000 -13.7200 9 N4x N 21.7000 -12.5300 10 C8y C 20.3000 -12.5300 11 C1y C 21.7000 -17.3600 12 C1y C 22.4000 -16.1700 13 X F 16.1000 -14.9800 14 C8y C 22.4000 -18.5500 15 C8x C 21.7000 -19.8100 16 C8x C 22.4000 -21.0000 17 C8y C 23.8000 -21.0000 18 C8x C 24.5000 -19.8100 19 C8x C 23.8000 -18.5500 20 X F 24.5700 -22.1900 21 C8y C 23.8000 -16.1700 22 N5x N 24.6400 -17.2900 23 C8x C 25.9700 -16.8000 24 N5x N 25.9700 -15.4000 25 N4y N 24.6400 -14.9800 26 O5x O 19.5300 -11.2700 27 C1a C 24.2200 -13.6500 28 N1x N 20.3000 -17.3600 29 C8y C 28.7700 -14.9800 30 C8x C 27.5100 -15.6800 31 C8x C 29.9600 -15.6800 32 S4a S 28.7700 -13.5800 33 C8x C 27.5100 -17.0800 34 C8x C 29.9600 -17.0800 35 O1d O 27.3700 -13.5800 36 O1d O 30.1700 -13.5800 37 O1d O 28.7700 -12.2500 38 C8y C 28.7700 -17.7800 39 C1a C 28.7700 -19.1800 BOND 43 1 1 2 2 2 2 3 1 3 3 4 2 4 4 5 1 5 5 6 2 6 1 6 1 7 4 7 1 8 7 8 2 9 8 9 1 10 9 10 1 11 5 10 1 12 11 12 1 13 12 7 1 14 1 13 1 15 14 15 2 16 15 16 1 17 16 17 2 18 17 18 1 19 18 19 2 20 14 19 1 21 17 20 1 22 11 14 1 #Up 23 12 21 1 #Down 24 21 22 2 25 22 23 1 26 23 24 2 27 24 25 1 28 21 25 1 29 10 26 2 30 25 27 1 31 3 28 1 32 28 11 1 33 29 30 1 34 29 31 2 35 29 32 1 36 30 33 2 37 31 34 1 38 32 35 2 39 32 36 2 40 32 37 1 41 33 38 1 42 38 39 1 43 34 38 2 |